%0 Generic
%A Piccart, M.
%A Borrego, M. Ruiz
%A Arkenau, H-T.
%A Escriva-De-Romani, S. I.
%A Howell, S. J.
%A Hennequin, A.
%A Jimenez-Rodriguez, B.
%A Del Conte, G.
%A Simonelli, M.
%A Palleschi, M.
%A Duhoux, F.
%A De Speville Uribe, B. Doger
%A Curigliano, G.
%A Waters, S.
%A Aftimos, P. G.
%A Wildiers, H.
%A Tosi, D.
%A Amair-Pinedo, F.
%A Pellacani, A. U. E.
%A Laurent, D. O.
%T MEN1611, a PI3K inhibitor, combined with trastuzumab (T) +/- fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01)
%D 2021
%@ 0923-7534
%U https://hdl.handle.net/10668/27098
%~